Breaking News
Get 50% Off 0
📖 Your Q2 Earnings Guide: Discover the Stocks ProPicks AI Highlights to Jump Post-Earnings Read more
Close

Supernus Pharmaceuticals Inc (SUPN)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Supernus's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
30.25 +1.15    +3.95%
19/07 - Closed. Currency in USD ( Disclaimer )
After Hours
30.25
0.00
0.00%
16:20:01 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 997,240
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 29.05 - 31.00
Supernus 30.25 +1.15 +3.95%

Supernus Pharmaceuticals Inc Company Profile

 
Get an in-depth profile of Supernus Pharmaceuticals Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

652

Equity Type

ORD

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company’s commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson’s Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company’s product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.

Contact Information

Address 9715 Key West Avenue
Rockville, 20850
United States
Phone 301 838 2500
Fax -

Top Executives

Name Age Since Title
Charles W. Newhall 76 2005 Independent Chairman of the Board
Jack A. Khattar 60 2005 Founder, President, CEO, Secretary & Director
Frederick M. Hudson 76 2010 Independent Director
Carrolee Barlow 61 2018 Independent Director
Georges Gemayel 64 2015 Independent Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

SUPN Comments

Write your thoughts about Supernus Pharmaceuticals Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
John Moris
John Moris Mar 02, 2021 1:02PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
good fundamentals, discount price, solid company. Nice price to add @ 25,20?
Josef Kurzmann
Josef Kurzmann Mar 02, 2021 1:02PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I'm waiting for $20 and maybe $15.
Josef Kurzmann
Josef Kurzmann Mar 02, 2021 1:02PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
the last earnings report was not good so that should put pressure on the stock price for now (at least until the next earnings report).
John Moris
John Moris Mar 02, 2021 1:02PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Josef Kurzmann what do you find it was not good in the last report?
Josef Kurzmann
Josef Kurzmann Mar 02, 2021 1:02PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
declining earnings and revenues compared to the prior quarter.
Josef Kurzmann
Josef Kurzmann Mar 02, 2021 1:02PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
i know if the earnings and revenues decline for 1 quarter it isn't a big thing but what will happen if they decline for 2 or 3 quarters, we would possible see $15
Josef Kurzmann
Josef Kurzmann Feb 23, 2021 9:52AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
i sold a couple of days ago, seems like the real market crash is finally coming. I'll re-visit SUPN in a couple of months and decide if the share price fell deep enough.
Josef Kurzmann
Josef Kurzmann Feb 09, 2021 8:58AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
yesterday i sent this stock as an "tip" to some stock advisors and hedge funds (only about 5 combined). the price rose 4.38% and today it is up 3.39% in the pre-market. i will tell more fund managers about this stock and then the price should jump really quick.
David Bieleski
David Bieleski Feb 09, 2021 8:58AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
That moment when Josef thinks he is moving markets
Josef Kurzmann
Josef Kurzmann Jan 30, 2021 3:00PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
one more time:I don't have the knowledge to make an educated guess if the FDA will or will not approve the new ADHD treatment and i am pretty sure you don't have the knowledge and insight eigther.What i know if that SUPN had a great balance sheet, is growing it's revenues 30% per year/earnings 40% per year both since 2016. I also know that their P/E ratio is at 12.5. so i can tell you, even if the new drug doesn't get approved the stock should be at around $90 per share (4.5 billion market cap). Right now it is at $30. If the new drug gets approved it should easily be at $100+ by the end of next year (December 2022) that is a 200%+ return in 23 months.
Hyborian War
HyborianWar Jan 30, 2021 3:00PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
BBRW
Josef Kurzmann
Josef Kurzmann Jan 29, 2021 8:33AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
supernus has a great risk/reward ratio. since 2016 earnings and revenues more than doubled yet the stock price is down 50% ($30 as I'm writing) . revenues and earnings are growing very fast (30%/40%p.a.) and this all makes it very likely that this stock quadrouples over the next 3-5 years.
Josef Kurzmann
Josef Kurzmann Jan 29, 2021 8:33AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
and i didn't even factor in that they have a new revolutionary treatment for ADHD in trial 3 that could be approved by the FDA (then the stock would be worth even more).
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email